Relationship between Early Inflammatory Response and Clinical Evolution of the Severe Multiorgan Failure in Mechanical Circulatory Support-Treated Patients
Table 2
Preimplant inflammatory characteristics.
All cases
max tSOFA score < 11
max tSOFA score ≥ 11
()
(Group A = 32)
Outcome + (group B = 8)
Outcome − (group C = 13)
TNF-, pg/mL
9.3 (5.2–12.1)
6.9 (5.0–10.4)
10.3 (2.6–16.3)
9.7 (9.4–14.0)
0.081
IL-6, pg/mL
9.8 (3.6–27.4)
6.8 (3.0–24.1)
17.8 (6.1–118.7)
25.6 (9.6–63.4)
0.067
IL-8, pg/mL
7.6 (5.2–13.6)
7.7 (5.5–11.3)
5.1 (3.7–14.4)
13.1 (5.3–24.2)
0.294
C-reactive protein, mg/dL
1.5 (0.5–3.9)
1.2 (0.3–3.1)
2.2 (0.8–13.1)
2.2 (1.1–8.4)
0.108
IL-10, pg/mL
1.8 (0–7.5)
1.8 (0–8.0)
1.7 (0–6.2)
2.2 (0–14.4)
0.824
IL-1ra, pg/mL
518 (311–1276)
491 (295–840)
785 (268–1955)
828 (468–1898)
0.137
sICAM-1, pg/mL
300 (224–433)
291 (226–397)
332 (220–676)
323 (210–528)
0.739
sP-selectin/PLT, pg/106
288 (164–505)
221 (173–476)
410 (217–622)
337 (122–537)
0.742
Neo/Cr ratio, mol/mol
290 (199–563)
279 (181–457)
317 (128–549)
337 (240–698)
0.422
Data are expressed as median and interquartile range (25th–75th). IL: interleukin; Neo/Cr: neopterin levels normalized by urine creatinine levels; sICAM-1: soluble form of intercellular adhesion molecule type 1; sP-selectin/PLT: soluble platelet selectin normalized by platelet count; TNF: tumor necrosis factor; +: positive; −: negative.
